This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. See study details page. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. See the table below for open treatment arms.

https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pediatric-match#1

For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Emailcancer@cchmc.org

 

TARGET

STUDY / ID

AGENT

KEY WORDS

DATE MODIFIED

STATUS

NA

SC

N/A

Screening Protocol

04/27/2020

OPEN

Pan-TRK inhibitor

A

LOXO-101 (larotrectinib)

NTRK Fusions

04/15/2019

OPEN

FGFR inhibitor

B

JNJ-42756493 (erdafitinib)

FGFR alterations

04/02/2019

OPEN

P13K/mTOR inhibitor

D

LY3023414

Solid tumors

04/01/2021

OPEN

ALK or ROS1 alterations

F

Ensartinib

ALK alterations, ROS1 alterations

10/05/2020

OPEN

BRAF inhibitor

G

vemurafenib

BRAF V600 mutations

12/21/2020

OPEN

PARP inhibitor

H

olaparib

Defects in DNA damage repair genes

11/19/2018

OPEN

CDK4 or 6 inhibitor

I

palbociclib

Activating Alterations in Cell Cycle Genes

12/30/2019

OPEN

IDH1 Mutations

K

Ivosidenib

IDH1 Mutations

10/26/2020

OPEN

HRAS genomic alterations

M

Tipifarnib

HRAS genomic alterations

06/14/2021

OPEN

RET Gene Alterations

N

LOXO-292

RET Gene Alterations

12/07/2020

OPEN